Donor-derived strongyloidiasis after organ transplantation in Norway.


Journal

Transplant infectious disease : an official journal of the Transplantation Society
ISSN: 1399-3062
Titre abrégé: Transpl Infect Dis
Pays: Denmark
ID NLM: 100883688

Informations de publication

Date de publication:
Feb 2019
Historique:
received: 09 07 2018
revised: 28 08 2018
accepted: 02 10 2018
pubmed: 9 10 2018
medline: 6 4 2019
entrez: 9 10 2018
Statut: ppublish

Résumé

Strongyloides stercoralis is an intestinal helminth which in humans can cause asymptomatic chronic infection maintained for decades through its auto-infective cycle. During solid organ transplantation, recipients may unintentionally receive an organ infected with strongyloides. This is a very rare complication but may have deadly outcome if not detected. We hereby report two transplant recipients whom developed Strongyloides hyperinfection syndrome after organ transplantation from the same deceased donor. Recipient 1 was kidney transplanted and presented at day 65 post engraftment with diarrhea and subsequent septicemia and gastric retention. Larvae were detected in gastric aspirate. Recipient 2 was simultaneously kidney and pancreas transplanted and presented at day 90 post engraftment also with gastric retention and septicemia. Larvae were demonstrated on duodenal biopsy and stool sample. The clinical course was complicated with severe duodenal bleedings, gastric retention, meningitis, and prolonged hospitalization. Retrospective testing of pre-transplant donor serum was positive for Strongyloides stercoralis antibodies. As a result of disease severity and gastric retention albenazole was administered via a jejunal tube and ivermectin subcutaneously in both recipients. S stercoralis was successfully eradicated and the transplants ended up with unaffected graft function. Following these two cases, we started systematic screening of all deceased donors for serum Strongyloides IgG in October 2016. After having screened 150 utilized donors one tested positive for Strongyloides, which initiated prophylactic ivermectin treatment to organ recipients. No symptoms or disease developed. Our center will continue to screen all donors as prophylactic treatment may avert this potentially lethal complication in cases of donor-derived Strongyloides infection.

Identifiants

pubmed: 30295406
doi: 10.1111/tid.13008
doi:

Substances chimiques

Antibodies, Helminth 0
Antiparasitic Agents 0

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e13008

Informations de copyright

© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Auteurs

Espen Nordheim (E)

Department of Transplantation Medicine, Oslo University Hospital - Rikshospitalet, Oslo, Norway.
Institute of Clinical Medicine, University of Oslo, Oslo, Norway.

Monica Olafsson Storrø (M)

Department of Transplantation Medicine, Oslo University Hospital - Rikshospitalet, Oslo, Norway.

Ane Kristine Natvik (AK)

Department of Infectious Diseases, Oslo University Hospital - Ullevål, Oslo, Norway.

Grete Birkeland Kro (G)

Department of Microbiology, Oslo University Hospital - Rikshospitalet, Oslo, Norway.

Karsten Midtvedt (K)

Department of Transplantation Medicine, Oslo University Hospital - Rikshospitalet, Oslo, Norway.

Anna Varberg Reisaeter (A)

Department of Transplantation Medicine, Oslo University Hospital - Rikshospitalet, Oslo, Norway.

Morten Hagness (M)

Department of Transplantation Medicine, Oslo University Hospital - Rikshospitalet, Oslo, Norway.

Børre Fevang (B)

Section of Clinical Immunology and Infectious Diseases, Oslo University Hospital, Oslo, Norway.
Research Institute of Internal Medicine, Oslo University Hospital, Oslo, Norway.

Frank O Pettersen (FO)

Regional Advisory Unit for Imported and Tropical Diseases, Department of Infectious Diseases, Oslo University Hospital - Ullevål, Oslo, Norway.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH